logo
logo

858 Therapeutics Launches With Proven Team And $60 Million Series A Financing

Sep 21, 2021•almost 4 years ago

Amount Raised

$60 Million

Round Type

series a

San Diego

Description

858 Therapeutics today exited stealth mode with a $60 million Series A financing led by founding investor Versant Ventures, with participation from NEA, Cormorant Asset Management and Logos Capital. Proceeds are being used to develop a portfolio of small molecules directed against novel therapeutic targets in oncology, including proteins that regulate RNA and the innate immune response.

Company Information

Company

858 Therapeutics

Location

San Diego, California, United States

About

858 Therapeutics is a biotechnology and drug discovery company developing a portfolio of small molecules directed against novel therapeutic targets in oncology, including proteins that regulate RNA and the innate immune response. The company has built a platform to assess the impact of RNA-modifying proteins on disease biology and has generated a pipeline of small molecules against priority targets. 858 is headquartered in the biotech hub of San Diego, CA, with operations also in New York City, providing proximity to leading investigators and scientific talent on both coasts of the U.S. For more information, please visit www.8five8tx.com.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech